The technology delivers fast results with few adverse events compared to topical, traditional UV, biologic and systemic therapies
STRATA Skin Sciences’ XTRAC technology is effective. (Credit: valelopardo from Pixabay.)
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the publication of a peer-reviewed health-economic study entitled: “Therapies for Psoriasis: Clinical and Economic Comparisons” in the November 2020 issue of the Journal of Drugs in Dermatology. The study was conducted by Dr. Albert Marchetti, a leading health economic researcher and an adjunct professor at Rutgers New Jersey Medical School, and compared common interventions to treat plaque psoriasis. The Company’s XTRAC excimer laser and its Optimal Therapeutic Dose (OTD™) treatment protocol utilizing the Multi Micro Dose™ (MMD®) diagnostic tip were found to deliver the fastest results with the fewest adverse events at the most economical cost of all treatments analyzed, including topical, traditional UV, biologic and systemic therapies. In addition, patients treated with the XTRAC excimer laser and XTRAC with MMD had fewer actual treatment days compared to all other modalities and was the only therapy where patients achieved remission without a maintenance therapy.
“This study was an extraordinarily comprehensive analysis of all treatment methodologies, so it is very gratifying to note that our XTRAC excimer laser and XTRAC with MMD devices were determined to be the best of all approaches, producing clinical outcomes comparable to the most effective biologics, at a fraction of the cost. This health economic assessment is very timely in light of the COVID19 pandemic, as psoriasis patients and providers now have increased concern over the use of biologics. The clinical and cost data from the study can help practitioners select appropriate treatments for patients currently using a biologic therapy and those with comorbidities,” said Dr. Dolev Rafaeli, STRATA’s President and Chief Executive Officer. “With over 600 integrated health systems, managing over 100 million patients, annually, the ability to offer a cost effective solution makes XTRAC the perfect alternative to other more expensive treatment options like Biologic drugs,“ concluded Dr. Rafaeli.
The XTRAC system is used in multiple Integrated Health System clinics; including Mt. Sinai, Kaiser Permanente and The United States Department of Veterans Affairs, in addition to its prevalent use by private practice physicians.
The study analyzed four main psoriasis therapeutic modalities; including topicals, systemics, phototherapy, and biologics. Researchers selected eight comparators (Methotrexate for systemics, Clobetasol (CLO) and Calcipotriene (CAL) combination for topicals and Etanercept (ETA), Infliximab (INF), and Ustekinumab (UST) for biologics, narrow-band UVB (NB-UVB), XTRAC with and without MMD technology (Optimal Therapeutic Dose OTD Protocol (published in the April 2020 issue of Journal of Drugs in Dermatology) for phototherapy) that were preferentially used within each category, widely studied, and supported by high-quality published research and data to represent each of the four modalities. Each therapy was analyzed for required care days, likelihood of response, speed and completeness of response, frequency and duration of remission, adverse events and their management, resource utilization, and cost.
Dr. Marchetti noted, “We were impressed by the effectiveness of the XTRAC technology and that it showed significant savings compared to other therapies. The study conclusions highlight the superiority of the XTRAC technology for treatment of psoriasis patients as being the least expensive, fastest onset, having the fewest adverse events, and having the ability to achieve remission without the need of maintenance therapy.”
Source: Company Press Release